Pfizer blocking research to generate evidence on optimal use of novel antiviral for COVID-19 patients in low- and middle-income countries

ANTICOV, Press Release, Mar 2022
ANTICOV reports that Pfizer has denied access to paxlovid for studies proposed by multiple groups. Also see1.
ANTICOV et al., 15 Mar 2022, preprint, 1 author.